Optiray (Ioversol)

Optiray is an iodinated contrast agent used in radiographic procedures that require enhanced visualization of internal anatomy.

• Computed Tomography (CT) scanning: improves delineation of vascular and soft‑tissue structures.
• Angiography: highlights blood vessels to aid in diagnosis and interventional planning.
• Intravenous urography: enhances urinary tract imaging for better detection of obstructions.
• Myelography: provides contrast for spinal canal evaluation.
• Cardiac CT: assists in coronary artery assessment.
• Pediatric imaging: offers safe contrast enhancement for children undergoing diagnostic scans.

• Ioversol is a non‑ionic, low‑osmolality iodinated compound that distributes rapidly in the extracellular fluid after intravenous injection. Its iodine atoms absorb X‑ray photons, increasing radiodensity of blood and tissues, which produces enhanced contrast on imaging studies without significantly altering physiological processes.

Adverse reactions to Optiray are generally related to its iodine content and route of administration.

Common Side Effects

• Warm sensation or flushing at the injection site.
• Nausea or mild vomiting.
• Headache.
• Transient metallic taste.
• Mild itching or urticaria.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis).
• Acute kidney injury, particularly in patients with pre‑existing renal impairment.
• Hypotension or cardiovascular collapse.
• Pulmonary edema.
• Seizures.
• Persistent skin rash or Stevens‑Johnson syndrome.

Optiray should be used with careful clinical assessment and monitoring.

• Renal function assessment: evaluate baseline kidney function before administration.
• Allergy history: screen for prior reactions to iodinated contrast agents.
• Hydration status: ensure adequate patient hydration to reduce renal risk.
• Cardiovascular status: monitor patients with heart failure or unstable hemodynamics.
• Concomitant nephrotoxic drugs: avoid or adjust dosing of other renal‑impacting medications.
• Store at ambient temperature: keep in original packaging, protect from light and moisture.

Optiray may interact with several medications that affect renal function or hypersensitivity risk.

Major Interactions (Avoid)

• Metformin: increased risk of lactic‑acidosis when renal function declines after contrast exposure.
• NSAIDs: combined nephrotoxic potential may exacerbate kidney injury.

Moderate Interactions (Monitor Closely)

• ACE inhibitors/ARBs: may potentiate contrast‑induced nephropathy; monitor renal parameters.
• Diuretics: can affect fluid balance and renal clearance; adjust hydration as needed.
• Beta‑blockers: may mask early signs of anaphylaxis; observe closely.
• Thyroid hormones: iodine load can alter thyroid function tests; check levels if clinically indicated.
• Radiopharmaceuticals: overlapping imaging agents may affect diagnostic interpretation.